TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change of patient autonomy
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Re-rupture
Endpoint domain: Adverse events/effects
Primary endpoint: Knee Score ve Knee Injury & Osteoarthritis Outcome (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in health promoting behaviours
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cognitive Measures (Eye-Tracking Metrics)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change on the visual analog scale (VAS) for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sonographic severity grade of shoulder impingement syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of premenstrual symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Assessment of stress level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Attenuation of production of inflammatory mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pain score at 15 minutes post medication administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score at 30 minutes post medication administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Stress Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mass Balance recovery (%Ae)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of obstructive lung function reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Numbers of patients diagnosed with obstructive lung function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Impact on the number of hospital visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Performance in diagnosing thyroid nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Early gastric cancer detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity and specificity of SavvyCheck Vaginal Yeast Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemoglobin (gm%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: serum Ferritin level (mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 7-day point prevalence of self-reported smoking cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to stability during stepdown task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Residual Viable Tumor Cells (% RVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Concordance between tracers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in baseline adjusted LDL-c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in baseline adjusted TMAO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of blood glucose readings at target glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in activation of mPFC, amygdala, and nucleus accumbens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mean plasma difference in sFlt-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective measles antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients with access to wearable device
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change of Gingival recession from baseline to 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Gingival recession from baseline to 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vein Occlusion Rate at 30 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Dosage of Bowel Cleansing Agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Numerical Pain Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee injury and Osteoarthritis Outcome Score for patellofemoral pain and osteoarthritis (KOOS-PF)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prevalence of multiple antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Assessment of Non-alcoholic fatty liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of MRD conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total benzodiazepine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of First-Degree Relatives to complete the AI-ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of First-Degree relatives to complete cardiac screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of Life for Epilepsy in Adolescents scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Vaccine-related serious adverse event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Grade ≥3 vaccine-related unsolicited adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Bacteriologically confirmed TB-related unfavorable outcome (treatment failure, TB recurrence, or death due to TB)
Endpoint domain: Mortality/survival
Primary endpoint: Intended dose received
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in sleep physiology
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Patent frontal sinusotomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: success of predictivity cervical consistency index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anterior uterocervical angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: posterior uterocervical angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuromelanin-sensitive MRI contrast-to-noise ratio (CNR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glutamate/glycine magnetic resonance spectroscopy (MRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain in oral cavity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Orthodontic-induced inflammatory root resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Percent of time with sensor glucose less than 70 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of time with sensor glucose less than 54 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of time with sensor glucose greater than 250 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Women's Physical Activity Self-Worth Inventory
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the number of hypoglycemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: State and Trait Anxiety Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrophic vaginal changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Current back-pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adenoma Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of complications associated with KC surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Soft tissue dehiscence depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: White matter changes in MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Biochemical changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of aneurysm rupture or critical growth
Endpoint domain: Mortality/survival
Primary endpoint: Usage of the intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Perceived usefulness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence and Severity of Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Lung Cancer Screening Knowledge scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Lung Cancer Screening Eligibility self-assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant Lung Cancer Screening Attitudes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Treatment-induced Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pain assessment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence, severity, causal relationship of treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: average dose of abemaciclib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants who Achieve ≥5% Body Weight Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Geometric Mean Concentration (GMC) of mRNA-1273.529 and mRNA-1273 Against the B.1.1.529 Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
Endpoint domain: Adverse events/effects
Primary endpoint: Alkaline Phosphatase (ALP) Test Result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Physician visit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Football Worry
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Moral Disengagement in Sport
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Positive Mental Health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Progression to preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of clinically not indicated preoperative diagnostic procedures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Identification of chromosomal regions associated with the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Identification of candidate genes for genetic susceptibility to infectious diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Validation of candidate genes as factor of susceptibility to infectious diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunoglobulin G (IgG) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in use of psychoactive medicinal drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Berg Balance Scale Post-intervention Assessment Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activities Specific Balance Scale (ABC) Post-intervention Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10 Meter Walk Test (10MWT) Post-intervention Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving target blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: insulin resistance (HOMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HRD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of pathological complete responses (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Implant complication rates
Endpoint domain: Adverse events/effects
Primary endpoint: Electrical performance of the pacing system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Parasomnia events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Nocturnal Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Nightmares
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Amount of oxycodone self-administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-report of oxycodone wanting
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-reported drug wanting from drug effects questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of treatment-emerging adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Diffusion capacity of carbon monoxide (DLCO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Capillary blood volume (Vc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Membrane diffusing capacity (Dm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Composite primary endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Covid-19 severe infection
Endpoint domain: Adverse events/effects
Primary endpoint: Covid-19 mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in Puberty development using the Tanner Stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum pain-free mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of Mean BCVA from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dosage of angiogenic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dosage of inflammatory markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma maximal concentration of galantamine (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of galantamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of ATV, PG and CG from Atoguanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of ATV, PG and CG for Atoguanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-72h of ATV, PG and CG for Atoguanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-168h of ATV for Atoguanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf of ATV, PG and CG for Atoguanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone remodeling markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Median Post-Procedural Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SpO2 ≤ 93% within 14 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Circulating tumoral cells detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Time to Peak (TTP) of meningeal lymphatic vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative delirium (POD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: WHODAS 2.0
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: service use and costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Medio-lateral and Anterior-posterior stability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemophilia joint health score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Adherence to the treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maintenance of results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion who complete screening/physical examination
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion who complete recommended cancer treatment modalities
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Detection of serum TGF β1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: volume of blood loss within 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Dose limited toxicity (DLT) of SHR-5495
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of SHR-5495
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase II Dose (RP2D) of SHR-5495
Endpoint domain: Adverse events/effects
Primary endpoint: Baseline Week ActiGraph Accelerometers-GT3X Return Rate at the End of the Baseline Week
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Return of ActiGraph Accelerometers-GT3X on Time by Post-baseline Week Participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Damaged or Lost ActiGraph Accelerometers-GT3X
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Post-stroke delirium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Post-stroke cognitive impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Radiological response evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from MACE (Major Adverse Clinical Events)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in abdominal bloating severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: family adaptation, partnership, growth, affection and resolve (APGAR) score
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Sleep Disturbances
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Incidence of anti-PD-1/PD-L1-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Estimation of energy intake (kcal) by children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Estimation of intake of food group servings by children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Estimation of energy intake (kcal) by parents or caregivers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Estimation of intake of food group servings by parents or caregivers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum levels of ferritin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hematopoietic stem cell transplant (HSCT) free survival
Endpoint domain: Mortality/survival
Primary endpoint: Kupperman Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Qualitative asymmetry of perilymphatic enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative signal intensity ratio of the cochlea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semi-quantitative scoring of endolymphatic hydrops
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative volume of endolymphatic and perilymphatic structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semi-quantitative analysis of the vestibule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stoma-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Health Insurance Literacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status